US Patent Issued to Regeneron Pharmaceuticals, Center for Non-Communicable Diseases SMC on July 28 for "Treatment of cerebrovascular disease with neurogenic locus notch homolog protein 3 (NOTCH3) agents" (New York Inventors)

ALEXANDRIA, Va., July 28 -- United States Patent no. 12,691,134, issued on July 28, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.) and Center for Non-Communicable Diseases SMC Private Ltd. (Karachi, Pakistan).

"Treatment of cerebrovascular disease with neurogenic locus notch homolog protein 3 (NOTCH3) agents" was invented by Juan Rodriguez-Flores (Tarrytown, N.Y.), Alan Shuldiner (Tarrytown, N.Y.), Aris Baras (Tarrytown, N.Y.), Danish Saleheen (Scarsdale, N.Y.) and Shareef Khalid (White Plains, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods of treating subjects having a cerebrovascular disease by administering Neurogenic Locus Notch Homolog Prote...